These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic value of the microRNA-29 family in patients with primary osteosarcomas.
    Author: Hong Q, Fang J, Pang Y, Zheng J.
    Journal: Med Oncol; 2014 Aug; 31(8):37. PubMed ID: 25015394.
    Abstract:
    The aim of this study was to facilitate and deepen the understanding of the associations of the microRNA-29 (miR-29) family with tumor progression and patients' prognosis of primary osteosarcoma. We examined expression levels of miR-29a, miR-29b, and miR-29c in tumor tissues and patients' sera of 80 cases of primary osteosarcomas by quantitative real-time reverse transcriptase-polymerase chain reaction. The correlations of their serum levels with clinicopathological characteristics and patient prognosis were also analyzed. The expression levels of miR-29a, miR-29b, and miR-29c in osteosarcoma tissues and patients' sera were all significantly higher than those in normal controls (all P < 0.05). The serum levels of miR-29a and miR-29b in the patients with higher tumor grade (both P = 0.01), positive metastasis (both P = 0.006), and positive recurrence (both P = 0.006) were both markedly higher than those with lower tumor grade, negative metastasis, and negative recurrence. According to the survival analysis of 80 osteosarcoma patients, cases in the miR-29a-high and miR-29b-high-expression groups both showed shorter overall survival (OS, both P < 0.001) and disease-free survival (DFS, both P < 0.001). Furthermore, the serum levels of miR-29a and miR-29b were both independent prognostic factors for OS and DFS of osteosarcoma patients. However, high miR-29c level was not related to any clinicopathological characteristics and patient prognosis of osteosarcomas (P > 0.05). The findings from the present study reveal that the miR-29 family may play crucial roles in the development and progression of human osteosarcoma. In particular, the serum levels of miR-29a and miR-29b may well estimate the prognosis of patients with this malignancy.
    [Abstract] [Full Text] [Related] [New Search]